A Deeper Look into New Therapies in the Management of Sickle Cell Disease: How the Latest Advances May Impact Decision-Making

A continuing medical education activity provided by NAMCP and AAMCN

New Horizons in the Management of Sickle Cell Disease (SCD): Leveraging Treatment Breakthroughs to Make Informed Decisions in Managed Care is a three-part webinar series

This is Part 2 of the series focusing on new therapies in the management of sickle cell disease

This activity is an archive from the webinar held December 10, 2020

This activity is valid from January 1, 2020 to January 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Global Blood Therapeutics and Novartis

Description:
Sickle cell disease (SCD) is a chronic, life-long, debilitating disease with many forms that can range in clinical severity from asymptomatic to life-threatening. In the US, SCD affects an estimated 90,000 to 100,000 Americans. This disease can lead to the obstruction of blood vessels, reduced blood flow to vital organs, and a weakened immune system. Fortunately for patients, novel therapies have been approved that have shown tremendous benefit in SCD.

Upon completion of this activity, participants will be able to:

  • Discuss the pathophysiology, physical manifestations, economic burden, clinical course, and impact on patient quality of life of sickle cell disease (SCD)

  • Examine the mechanisms underlying new and emerging treatments for patients with SCD that work upstream of sickle hemoglobin (HbS) polymerization and may be disease-modifying

  • Evaluate the latest clinical evidence regarding new and emerging disease-modifying options for patients with SCD and the implications for patients

  • Analyze the safety and efficacy of new therapies that manage acute vaso-occlusive pain events in SCD

  • Examine the latest understanding regarding SCD phenotypes and implications for treatment selection and sequencing

  • Identify patients with vaso-occlusive pain events in SCD for whom a newer therapy is an appropriate choice for the next step in the management of their disease

     

Faculty: Ahmar U. Zaidi, MD
Assistant Professor of Pediatrics
Division of Pediatric Hematology/Oncology
Central Michigan University SOM
Children’s Hospital of Michigan
Cooley & Whitten Center for Hemoglobinopathies

Disclosure:

Dr. Zaidi has served on advisory boards for Global Blood Therapeutics and Novartis. He has served as a consultant for Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Cyclerion, and bluebird bio. He has received grants/research support from Global Blood Therapeutics, Imara, and Emmaus Life Sciences. He serves on the speaker’s bureau for Global Blood Therapeutics.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Global Blood Therapeutics and Novartis

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue